인문학
사회과학
자연과학
공학
의약학
농수해양학
예술체육학
복합학
DBpia AI
AI 에이전트
AI 아이디어
AI 리더
AI 뷰어
Citeasy
크롬 서지관리 다운로드
지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록·키워드
Abstract Background Therapeutic approaches for addressing asymptomatic chronic kidney disease (CKD) with renal impairment requires careful consideration, as there is a lack of substantial evidence endorsing specific medications. This study examined the outcomes of administering febuxostat to persons diagnosed with asymptomatic hyperuricemia in CKD (stages 3 and 4). Methods A single-patient blinded; placebo-controlled study was carried out at Chittagong Medical College Hospital in Chattogram 4203 over a 1-year period. Participants were randomly assigned to two groups: one group received a daily dose of 40 mg of febuxostat while the other was given placebo tablets. As necessary, diuretics, antihypertensives, and antidiabetics were administered. Evaluations, which included patient history, physical examinations, outcomes, and pertinent tests, were performed at baseline, the 3rd month, and the 6th month. Results There were 105 similar-baseline patients in each group. The mean serum uric acid (SUA) level in the febuxostat group lowered from 8.55 to 4.92 mg/dL after 6 months, while in the placebo control it elevated from 8.10 to 8.99. In febuxostat group, the mean eGFR elevated from 25.28 to 27.01 ml/min/1.73 m 2 , while in the placebo control it reduced from 26.81 to 23.32. In the febuxostat group, at the 6-month mark, eGFR differed across groups following a substantial decrease in systolic and diastolic blood pressure ( P < 0.05). Conclusions In our clinical setting, febuxostat proved more effective than a placebo in reducing serum uric acid levels and maintaining eGFR in patients with stage 3 and 4 CKD. Hence, febuxostat could be employed to treat hyperuricemia-associated asymptomatic chronic renal disease.
인공지능 문자 인식 모델을 통해 추출된 텍스트로, 일부 오타나 오류가 포함될 수 있으나 지속적으로 개선 중입니다.
오류를 발견하셨다면 해당 부분을 드래그한 후 ' 를 통해 신고해주세요.
오류를 발견하셨다면 해당 부분을 드래그한 후 ' 를 통해 신고해주세요.
최근 본 자료 전체보기
